These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Efficacy, safety and acceptability of a seven-day, transdermal estradiol patch for estrogen replacement therapy. Jarupanich T; Lamlertkittikul S; Chandeying V J Med Assoc Thai; 2003 Sep; 86(9):836-45. PubMed ID: 14649968 [TBL] [Abstract][Full Text] [Related]
23. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy. Hirvonen E; Lamberg-Allardt C; Lankinen KS; Geurts P; Wilén-Rosenqvist G Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():19-25. PubMed ID: 9389779 [TBL] [Abstract][Full Text] [Related]
24. A comparison of transdermal and oral HRT for menopausal symptom control. Akhila V; Pratapkumar Int J Fertil Womens Med; 2006; 51(2):64-9. PubMed ID: 16881381 [TBL] [Abstract][Full Text] [Related]
25. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms. Van Leusden HA; Albertyn G; Verlaine C; Van Ruymbeke J Int J Fertil Menopausal Stud; 1993; 38(4):210-8. PubMed ID: 8401679 [TBL] [Abstract][Full Text] [Related]
26. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins. Bhathena RK; Anklesaria BS; Ganatra AM; Pinto R Br J Clin Pharmacol; 1998 Feb; 45(2):170-2. PubMed ID: 9491833 [TBL] [Abstract][Full Text] [Related]
31. New developments in topical estrogen therapy. Jewelewicz R Fertil Steril; 1997 Jan; 67(1):1-12. PubMed ID: 8986674 [TBL] [Abstract][Full Text] [Related]
32. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. Gordon SF Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298 [TBL] [Abstract][Full Text] [Related]
33. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. Weissberger AJ; Ho KK; Lazarus L J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807 [TBL] [Abstract][Full Text] [Related]
34. The long-term tolerability and efficacy of OESCLIM: results of a 1-year study. Taurelle R; L'Hermite M; Haenggi W; Lauritzen C; Studd JW Maturitas; 1999 Nov; 33 Suppl 1():S73-81. PubMed ID: 10661618 [TBL] [Abstract][Full Text] [Related]
37. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516 [TBL] [Abstract][Full Text] [Related]
38. Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Padwick ML; Endacott J; Whitehead MI Am J Obstet Gynecol; 1985 Aug; 152(8):1085-91. PubMed ID: 3927737 [TBL] [Abstract][Full Text] [Related]
39. Transdermal oestrogen replacement therapy in a Finnish population. Erkkola R; Holma P; Järvi T; Nummi S; Punnonen R; Raudaskoski T; Rehn K; Ryynänen M; Sipilä P; Tunkelo E Maturitas; 1991 Oct; 13(4):275-81. PubMed ID: 1775081 [TBL] [Abstract][Full Text] [Related]
40. Transdermal oestrogen for postmenopausal women: a double blind crossover comparative study with ethinyl oestradiol. Pattison NS; Uptin T; Knox B; France J Aust N Z J Obstet Gynaecol; 1989 Feb; 29(1):62-5. PubMed ID: 2562605 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]